Drug intelligence / Profile preview

PIEX 62% CBD concentrate

Development stage: Unknown
Lead developer: Becanex
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Inhalation, Oral, Rectal, Topical

Overview

PIEX 62% CBD concentrate (also known as PIEX 3) is a standardized, full-spectrum botanical cannabis extract developed by Becanex. Derived from the indica-dominant God Bud cultivar, this pharmaceutical-grade raw extract contains a stable cannabidiol (CBD) content of 62% and a tetrahydrocannabinol (THC) content below 5%. It preserves the natural cannabinoid, terpene, and flavonoid profile of the source flower, with five main terpenes representing over 70% of the total terpene content. The extract is designed for medical cannabis therapy, where it can be administered via inhalation (vaporization) or compounded by pharmacies into capsules, suppositories, oral solutions, or topical preparations. Its therapeutic effects are mediated through interactions with cannabinoid receptors (CB1 and CB2).

Brand names: Becanex PIEX 3 62% CBD RohextraktPIEX 3 62% CBD RohextraktPIEX 62% CBD Rohextrakt
Other names: 62% CBD concentrate line

Targets

CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)

Beyond the preview

Go deeper on PIEX 62% CBD concentrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PIEX 62% CBD concentrate.